title: [Cholesterol-lowering effect of the regulatory peptide Pro-Gly-Pro-Leu].
abstract: In the present paper anticoagulant-fibrinolytic effects of the peptide Pro-Gly-Pro-Leu in rats (370-500 g body weight) who consumed fatty foods with excess of saturated fatty acids (wheat flour and bread--35%, sugar--10%, margarine hydrogenated fats, mayonnaise, cheese--35% and offals--10%, cholesterol--1%, dry food--9%) has been established. The duration of the animals on the diet was 15 days. The experimental animals intranasally obtained peptide (200 microg/kg body weight per volume of 0.02 ml per 200 g body weight) 11 times (daily except weekends). Animals from the control group intranasally received instead of peptide its vehicle (0.85% solution of NaCl) at the same time and in the same amount. It has been shown that daily nasal administration of the regulatory tetrapeptide under fatty food intake for the entire period of the experiment has a positive effect on lipid metabolism. It warned the development of alimentary hypercholesterolemia, an increase in body weight, normalized disturbed lipid profile, blood cholesterol level. In addition, its administration also restored functional status of anticoagulation system and decreased elevated degree of blood coagulation to normal values. Possible mechanism of hypocholesterolemic activity of peptide can be explained by its ability to interact with receptors of blood or brain cells, and through a series of reactions mediated to reduce blood cholesterol levels. Thanks to the anti-platelet activity glyprolines effectively improves endothelial function and reduces the risk of blood clots in the blood vessels, providing improved rheological properties of blood and preventing the formation of atherosclerotic plaques in the arterial wall.
authors.forename: N F
authors.initials: NF
authors.lastname: Miasoedov
authors.forename: T A
authors.initials: TA
authors.lastname: Shubina
authors.forename: T Iu
authors.initials: TIu
authors.lastname: Obergan
authors.forename: M E
authors.initials: ME
authors.lastname: Grigor'eva
authors.forename: L A
authors.initials: LA
authors.lastname: Andreeva
authors.forename: L A
authors.initials: LA
authors.lastname: Liapina
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood*; D004041:Dietary Fats / Q000009:adverse effects*; D004195:Disease Models, Animal; D006487:Hemostasis / Q000187:drug effects; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D001786:Blood Glucose; D004041:Dietary Fats; D009842:Oligopeptides; C551701:prolyl-glycyl-prolyl-leucine; D002784:Cholesterol